Log In
BCIQ
Print this Print this
 

DCR-PHXC

  Manage Alerts
Collapse Summary General Information
Company Dicerna Pharmaceuticals Inc.
DescriptionSubcutaneously delivered GalXC clinical candidate
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHyperoxaluria
Indication DetailsTreat primary hyperoxaluria type 1
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today